Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2022-04, Vol.386 (14), p.1377-1380 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1380 |
|---|---|
| container_issue | 14 |
| container_start_page | 1377 |
| container_title | The New England journal of medicine |
| container_volume | 386 |
| creator | Regev-Yochay, Gili Gonen, Tal Gilboa, Mayan Mandelboim, Michal Indenbaum, Victoria Amit, Sharon Meltzer, Lilac Asraf, Keren Cohen, Carmit Fluss, Ronen Biber, Asaf Nemet, Ital Kliker, Limor Joseph, Gili Doolman, Ram Mendelson, Ella Freedman, Laurence S Harats, Dror Kreiss, Yitshak Lustig, Yaniv |
| description | Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease. |
| doi_str_mv | 10.1056/NEJMc2202542 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9006792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2647707108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c621t-f087879c08ab63cf33ad33028cc2d85cf2053d9aa3b9454192491749f5398a163</originalsourceid><addsrcrecordid>eNptkc1LAzEQxYMotlZvnmVBDx5czedmcxG0tn5QWxD1GtJsoindjW62hf73prRKFXMZyPx482YeAIcIniPIsoth7-FRYwwxo3gLtBEjJKUUZtugDSHOU8oFaYG9ECYwPkTFLmgRhgVnArXBdc9ap5VeJN4mKun7Wd28Jzc-mOVH189dkSKRlE_Dq-RVae0qk6g35arQJKPS6dpX-2DHqmkwB-vaAS_93nP3Lh2Mbu-7V4NUZxg1qYU5z7nQMFfjjGhLiCoIiQ61xkXOtMWQkUIoRcaCMooEpgJxKiwjIlcoIx1wudL9mI1LU2hTNbWayo_alapeSK-c_N2p3Lt883MpIMy4wFHgdC1Q-8-ZCY0sXdBmOlWV8bMgcUYhwdHTctbxH3QSL1PF9ZYU55AjmEfqbEXFM4RQG_tjBkG5DEduhhPxo80FfuDvNCJwsgLKMsjKTMr_db4AW8iRmA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2647707108</pqid></control><display><type>article</type><title>Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Regev-Yochay, Gili ; Gonen, Tal ; Gilboa, Mayan ; Mandelboim, Michal ; Indenbaum, Victoria ; Amit, Sharon ; Meltzer, Lilac ; Asraf, Keren ; Cohen, Carmit ; Fluss, Ronen ; Biber, Asaf ; Nemet, Ital ; Kliker, Limor ; Joseph, Gili ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Harats, Dror ; Kreiss, Yitshak ; Lustig, Yaniv</creator><creatorcontrib>Regev-Yochay, Gili ; Gonen, Tal ; Gilboa, Mayan ; Mandelboim, Michal ; Indenbaum, Victoria ; Amit, Sharon ; Meltzer, Lilac ; Asraf, Keren ; Cohen, Carmit ; Fluss, Ronen ; Biber, Asaf ; Nemet, Ital ; Kliker, Limor ; Joseph, Gili ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Harats, Dror ; Kreiss, Yitshak ; Lustig, Yaniv</creatorcontrib><description>Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2202542</identifier><identifier>PMID: 35297591</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antibodies ; Confidence intervals ; Coronavirus ; Coronaviruses ; Correspondence ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 - virology ; COVID-19 vaccines ; COVID-19 Vaccines - therapeutic use ; Health care ; Humans ; Immunization, Secondary - methods ; Infections ; Infectious Disease ; Medical personnel ; mRNA ; mRNA vaccines ; mRNA Vaccines - therapeutic use ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine Efficacy ; Vaccines ; Vaccines, Synthetic ; Viral Infections</subject><ispartof>The New England journal of medicine, 2022-04, Vol.386 (14), p.1377-1380</ispartof><rights>Copyright © 2022 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c621t-f087879c08ab63cf33ad33028cc2d85cf2053d9aa3b9454192491749f5398a163</citedby><cites>FETCH-LOGICAL-c621t-f087879c08ab63cf33ad33028cc2d85cf2053d9aa3b9454192491749f5398a163</cites><orcidid>0000-0001-7163-4607 ; 0000-0003-1734-9391 ; 0000-0001-6007-0383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2202542$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2647707108?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,782,786,887,2761,2762,26110,27931,27932,52389,54071,64392,64394,64396,72476</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35297591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Regev-Yochay, Gili</creatorcontrib><creatorcontrib>Gonen, Tal</creatorcontrib><creatorcontrib>Gilboa, Mayan</creatorcontrib><creatorcontrib>Mandelboim, Michal</creatorcontrib><creatorcontrib>Indenbaum, Victoria</creatorcontrib><creatorcontrib>Amit, Sharon</creatorcontrib><creatorcontrib>Meltzer, Lilac</creatorcontrib><creatorcontrib>Asraf, Keren</creatorcontrib><creatorcontrib>Cohen, Carmit</creatorcontrib><creatorcontrib>Fluss, Ronen</creatorcontrib><creatorcontrib>Biber, Asaf</creatorcontrib><creatorcontrib>Nemet, Ital</creatorcontrib><creatorcontrib>Kliker, Limor</creatorcontrib><creatorcontrib>Joseph, Gili</creatorcontrib><creatorcontrib>Doolman, Ram</creatorcontrib><creatorcontrib>Mendelson, Ella</creatorcontrib><creatorcontrib>Freedman, Laurence S</creatorcontrib><creatorcontrib>Harats, Dror</creatorcontrib><creatorcontrib>Kreiss, Yitshak</creatorcontrib><creatorcontrib>Lustig, Yaniv</creatorcontrib><title>Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.</description><subject>Antibodies</subject><subject>Confidence intervals</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>Correspondence</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 - virology</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - therapeutic use</subject><subject>Health care</subject><subject>Humans</subject><subject>Immunization, Secondary - methods</subject><subject>Infections</subject><subject>Infectious Disease</subject><subject>Medical personnel</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>mRNA Vaccines - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic</subject><subject>Viral Infections</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkc1LAzEQxYMotlZvnmVBDx5czedmcxG0tn5QWxD1GtJsoindjW62hf73prRKFXMZyPx482YeAIcIniPIsoth7-FRYwwxo3gLtBEjJKUUZtugDSHOU8oFaYG9ECYwPkTFLmgRhgVnArXBdc9ap5VeJN4mKun7Wd28Jzc-mOVH189dkSKRlE_Dq-RVae0qk6g35arQJKPS6dpX-2DHqmkwB-vaAS_93nP3Lh2Mbu-7V4NUZxg1qYU5z7nQMFfjjGhLiCoIiQ61xkXOtMWQkUIoRcaCMooEpgJxKiwjIlcoIx1wudL9mI1LU2hTNbWayo_alapeSK-c_N2p3Lt883MpIMy4wFHgdC1Q-8-ZCY0sXdBmOlWV8bMgcUYhwdHTctbxH3QSL1PF9ZYU55AjmEfqbEXFM4RQG_tjBkG5DEduhhPxo80FfuDvNCJwsgLKMsjKTMr_db4AW8iRmA</recordid><startdate>20220407</startdate><enddate>20220407</enddate><creator>Regev-Yochay, Gili</creator><creator>Gonen, Tal</creator><creator>Gilboa, Mayan</creator><creator>Mandelboim, Michal</creator><creator>Indenbaum, Victoria</creator><creator>Amit, Sharon</creator><creator>Meltzer, Lilac</creator><creator>Asraf, Keren</creator><creator>Cohen, Carmit</creator><creator>Fluss, Ronen</creator><creator>Biber, Asaf</creator><creator>Nemet, Ital</creator><creator>Kliker, Limor</creator><creator>Joseph, Gili</creator><creator>Doolman, Ram</creator><creator>Mendelson, Ella</creator><creator>Freedman, Laurence S</creator><creator>Harats, Dror</creator><creator>Kreiss, Yitshak</creator><creator>Lustig, Yaniv</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7163-4607</orcidid><orcidid>https://orcid.org/0000-0003-1734-9391</orcidid><orcidid>https://orcid.org/0000-0001-6007-0383</orcidid></search><sort><creationdate>20220407</creationdate><title>Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron</title><author>Regev-Yochay, Gili ; Gonen, Tal ; Gilboa, Mayan ; Mandelboim, Michal ; Indenbaum, Victoria ; Amit, Sharon ; Meltzer, Lilac ; Asraf, Keren ; Cohen, Carmit ; Fluss, Ronen ; Biber, Asaf ; Nemet, Ital ; Kliker, Limor ; Joseph, Gili ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Harats, Dror ; Kreiss, Yitshak ; Lustig, Yaniv</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c621t-f087879c08ab63cf33ad33028cc2d85cf2053d9aa3b9454192491749f5398a163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Confidence intervals</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>Correspondence</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 - virology</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - therapeutic use</topic><topic>Health care</topic><topic>Humans</topic><topic>Immunization, Secondary - methods</topic><topic>Infections</topic><topic>Infectious Disease</topic><topic>Medical personnel</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>mRNA Vaccines - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic</topic><topic>Viral Infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Regev-Yochay, Gili</creatorcontrib><creatorcontrib>Gonen, Tal</creatorcontrib><creatorcontrib>Gilboa, Mayan</creatorcontrib><creatorcontrib>Mandelboim, Michal</creatorcontrib><creatorcontrib>Indenbaum, Victoria</creatorcontrib><creatorcontrib>Amit, Sharon</creatorcontrib><creatorcontrib>Meltzer, Lilac</creatorcontrib><creatorcontrib>Asraf, Keren</creatorcontrib><creatorcontrib>Cohen, Carmit</creatorcontrib><creatorcontrib>Fluss, Ronen</creatorcontrib><creatorcontrib>Biber, Asaf</creatorcontrib><creatorcontrib>Nemet, Ital</creatorcontrib><creatorcontrib>Kliker, Limor</creatorcontrib><creatorcontrib>Joseph, Gili</creatorcontrib><creatorcontrib>Doolman, Ram</creatorcontrib><creatorcontrib>Mendelson, Ella</creatorcontrib><creatorcontrib>Freedman, Laurence S</creatorcontrib><creatorcontrib>Harats, Dror</creatorcontrib><creatorcontrib>Kreiss, Yitshak</creatorcontrib><creatorcontrib>Lustig, Yaniv</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Regev-Yochay, Gili</au><au>Gonen, Tal</au><au>Gilboa, Mayan</au><au>Mandelboim, Michal</au><au>Indenbaum, Victoria</au><au>Amit, Sharon</au><au>Meltzer, Lilac</au><au>Asraf, Keren</au><au>Cohen, Carmit</au><au>Fluss, Ronen</au><au>Biber, Asaf</au><au>Nemet, Ital</au><au>Kliker, Limor</au><au>Joseph, Gili</au><au>Doolman, Ram</au><au>Mendelson, Ella</au><au>Freedman, Laurence S</au><au>Harats, Dror</au><au>Kreiss, Yitshak</au><au>Lustig, Yaniv</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2022-04-07</date><risdate>2022</risdate><volume>386</volume><issue>14</issue><spage>1377</spage><epage>1380</epage><pages>1377-1380</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Health care workers in Israel were given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant predominance. Levels of antibodies to SARS-CoV-2 had waned 5 months after a third dose, and the fourth dose boosted antibodies to the maximum level observed after the third dose but no higher. Vaccine efficacy was 31 to 43% against symptomatic disease.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>35297591</pmid><doi>10.1056/NEJMc2202542</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-7163-4607</orcidid><orcidid>https://orcid.org/0000-0003-1734-9391</orcidid><orcidid>https://orcid.org/0000-0001-6007-0383</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2022-04, Vol.386 (14), p.1377-1380 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9006792 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antibodies Confidence intervals Coronavirus Coronaviruses Correspondence COVID-19 COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - therapeutic use Health care Humans Immunization, Secondary - methods Infections Infectious Disease Medical personnel mRNA mRNA vaccines mRNA Vaccines - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine Efficacy Vaccines Vaccines, Synthetic Viral Infections |
| title | Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T23%3A32%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20a%20Fourth%20Dose%20of%20Covid-19%20mRNA%20Vaccine%20against%20Omicron&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Regev-Yochay,%20Gili&rft.date=2022-04-07&rft.volume=386&rft.issue=14&rft.spage=1377&rft.epage=1380&rft.pages=1377-1380&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2202542&rft_dat=%3Cproquest_pubme%3E2647707108%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2647707108&rft_id=info:pmid/35297591&rfr_iscdi=true |